Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning
Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins
You may also be interested in...
After a warning letter, Embeda sales effort focuses on specialists. Firm does not see franchise threat from generics, although Remoxy will not be refiled until the middle of next year.
Purdue's OxyContin will get another advisory committee review Sept. 24, 2009, in light of new data.
Embeda to launch in September backed by 610 sales reps, Chief Commercial Officer Andrzejewski says.